Field Trip Health is partnering with online mental health platform, Cerebral, to provide improved mental health care.
Through the partnership, Cerebral clinicians will be able to refer qualified clients to Field Trip Health‘s ketamine-assisted therapy. At the same time, Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral.
Field Trip executive chairman, Ronan Levy, commented: “Our partnership with Cerebral will lower the barriers of entry into ketamine assisted therapy for many people who have solely been exposed to generalised psychiatry or might have not been presented with an alternative of exploring a healing journey propelled through psychedelics.
”We’re excited to be Cerebral’s preferred platform to refer patients to. Together we will help change the mental health landscape by bringing together teletherapy, telepsychiatry, and psychedelic-assisted therapy and offer more comprehensive benefits to consumers’ mental health.”
The two health companies hope that this end-to-end approach to mental health care will help to provide patients with personalised treatment solutions.
Cerebral chief medical officer, Dr David Mou, stated: “The recent shift in the mental health landscape has resulted in a need for modernised, digitised, and personalised solutions. At its core, Cerebral believes that everyone deserves access to individualised, non-judgmental mental health care.
“We’re constantly searching for novel ways to work towards that goal, which is why we chose to partner with Field Trip, a like-minded company with an aligning ethos that brings psychedelic-assisted psychotherapy to the table for our clients.”
Psychedelic healthcare provider Field Trip Health has clinics in eight US cities, and launched its first European therapy centre in the Netherlands in early 2021, Field Trip Health is providing psychedelic healing experiences using truffles.
Speaking to Psychedelic Health previously, Levy stated: “We are working to fulfil this mission by establishing a best-in-class network of Field Trip Health centres around the world, aiming to have 75 locations by 2024 and by developing the best-in-class psychedelic medicines, such as our novel psychedelic molecule, FT-104, which we believe will be an incredibly effective treatment for treatment-resistant depression and post-partum depression.”
[activecampaign form=52]
